Whalesbook
Cipla's stock price surged on May 14, 2026, climbing as much as 7.9% to an intraday high of ₹1,432.10 on the NSE. This rally occurred despite the company reporting a significant 55% year-on-year drop in consolidated net profit to ₹554.6 crore for the fourth quarter of fiscal year 2026. Revenue also decreased 2.8% to ₹6,541.2 crore. Operating profit (EBITDA) contracted 35.17% year-on-year to ₹997 crore, with EBITDA margins narrowing to 15.2% from 22.8% in the same quarter last year. The market's positive reaction suggests investors are looking past current financials, anticipating a turnaround from upcoming product launches and a recovery in key markets. The company aims for $1 billion in U.S. annual sales by fiscal year 2027.
Cipla's domestic business showed resilience, growing 15% year-on-year in Q4 FY26. However, its North America segment dropped 30% on a constant currency basis, generating $155 million for the quarter. This decline was due to factors like the absence of gRevlimid and supply disruptions for Lanreotide. The U.S. generic drug market, a key revenue source, faces structural issues like intense pricing pressure and fragile supply chains. While the U.S. generic market is projected to grow, economic realities and many unlaunched approved generics point to a tough competitive environment. Other sector players show mixed results: Dr. Reddy's Laboratories reported a P/E of 19.01x with a 1-year return of 6.25%, while Lupin's Q4 FY26 profit doubled on strong US generics performance before its stock dipped slightly. Cipla is working to boost its US presence, including recent FDA approval for its generic Ventolin inhaler, which analysts estimate could generate $100 million in sales. The Indian pharmaceutical sector is expected to grow steadily, with the Indian Pharma Market (IPM) projected to grow 7.8%-8.1% in 2026. Cipla's full-year FY26 revenue reached ₹28,163 crore, with its One-India business surpassing ₹12,500 crore annually. Despite domestic strengths, meeting its target of $1 billion in US sales by FY27 and achieving 18.5-20% EBITDA margins for FY27 relies on future launches, facing significant market hurdles and execution risks.
Despite optimistic forecasts from some brokerages and management, significant risks cloud Cipla's outlook. The ambitious targets of $1 billion in US sales by FY27 and 18.5-20% EBITDA margins for FY27 appear challenging given current US generics market weaknesses. Pricing pressures are intensifying, and many FDA-approved generics have historically failed to launch due to poor economics. Recent US FDA observations at Pharmathen and Cipla's Indore facility raise concerns about supply chain reliability, potentially delaying key product launches. For example, while the generic Ventolin inhaler is anticipated, past supply disruptions have negatively impacted Cipla's stock. Key competitors like Sun Pharma and Dr. Reddy's Laboratories are also navigating competitive US markets. Some analysts note that major Indian drugmakers, including Cipla, have had trouble sustaining stock breakouts. Cipla's market share in India has also slightly decreased over the last five years, from 6.88% to 6.7%. The proposed final dividend of ₹13 per share may offer some support but doesn't change the underlying operational challenges.
Looking ahead, Cipla's strategy relies on successful execution of upcoming launches and recovery in its North American business. JM Financial has upgraded its rating to 'Buy' with a target price of ₹1,546, expecting improved earnings momentum from the second half of FY27. Nomura maintains a 'Buy' rating and a target of ₹1,510. In contrast, Motilal Oswal Financial Services remains 'Neutral' with a target price of ₹1,380, citing reduced contribution from g-lenalidomide and a gestation period for new niche launches. Revitalizing US performance alongside sustained domestic growth will shape Cipla's stock trajectory through FY27.